US4925736A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical hematoporphyrin
Assignee: Long Island Jewish Medical Center
•
Filing: 1988-07-06
•
Granted: 1990-05-15
•
Expires: 2008-07-06
Abstract
No abstract record available.
Inventors
- 👤 Mark J. Shikowitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 13:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K47/00; A61K47/06; A61K47/20; A61K9/00; A61K9/0012; A61K9/0014; A61P; A61P35/00
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
29 words
A non-lyophilized topical composition for photodynamic therapy, comprising a photoreactive agent dispersed in a carrier vehicle which is capable of deep penetration when applied to mammalian skin or mucosa.
Claim 2
Dependent Claim
29 words
A non-lyophilized topical composition for photodynamic therapy, comprising a photoreactive agent dispersed in a carrier vehicle which is capable of deep penetration when applied to mammalian skin or mucosa.
Claim 3
Dependent Claim
20 words
The composition of claim 1, wherein the concentration of said photodynamic agent is from about 1 to about 7.5 mg/ml.
Claim 4
Dependent Claim
16 words
The composition of claim 2, wherein the concentration of said photodynamic agent is about 2.5 mg/ml.
Claim 5
Dependent Claim
15 words
The composition of claim 2, wherein said photoreactive agent comprises HPD, DHE, or mixtures thereof.
Claim 6
Dependent Claim
15 words
The composition of claim 4, wherein said carrier vehicle comprises a hydrophilic gel or cream.
Claim 7
Dependent Claim
14 words
The composition of claim 4, wherein said carrier vehicle has a high alcohol content.
Claim 8
Dependent Claim
35 words
The composition of claim 6, wherein said carrier vehicle comprises about 50% w/w SD alcohol, the remainder comprising one or more of propylene glycol, purified water, polyoxyethylene lauryl ether dioctyl sodium sulfosuccinate, and the like.
Claim 9
Dependent Claim
28 words
The composition of claim 6, wherein said carrier comprises 54% by weight SD alcohol, the remainder comprising propylene glycol, purified water, polyoxyethylene lauryl ether, and dioctyl sodium sulfosuccinate.
Claim 10
Dependent Claim
11 words
The composition of claim 4, wherein said carrier vehicle comprises DMSO.
Claim 11
Dependent Claim
33 words
The composition of claim 4, wherein said photoreactive agent is capable of destroying areas of abnormal tissue growth when exposed to light having a wavelength of from about 625 to about 635 nm.
Claim 12
Dependent Claim
15 words
The composition of claim 10, wherein the abnormal tissue growth is caused by papillomavirus disease.
Claim 13
Dependent Claim
42 words
A process for preparing a topical composition for photodynamic therapy, comprising (a) concentrating an aqueous solution of a photoreactive agent to from about 20 to about 25% of its original volume; and (b) rediluting said agent in a penetrating topical carrier vehicle.
Claim 14
Dependent Claim
42 words
A process for preparing a topical composition for photodynamic therapy, comprising (a) concentrating an aqueous solution of a photoreactive agent to from about 20 to about 25% of its original volume; and (b) rediluting said agent in a penetrating topical carrier vehicle.
Claim 15
Dependent Claim
37 words
The process of claim 12, further comprising placing said agent in a vacuum of from about 20 to about 35 mm Hg at a temperature of from about 5° to about 15° C. during the concentration step.
Claim 16
Dependent Claim
23 words
The process of claim 12, further comprising mildly and constantly agitating the mixture of said agent and said carrier during the concentrating step.
Claim 17
Dependent Claim
24 words
The process of claim 12, further comprising mildly and constantly agitating the mixture of said agent and said carrier vehicle during the rediluting step.
Claim 18
Dependent Claim
32 words
The process according to claim 12, further comprising applying said composition to a diseased area of mammalian skin, and thereafter exposing the area to light having a wavelength in the red spectrum.
Claim 19
Dependent Claim
25 words
The process according to claim 16, further comprising exposing the diseased area to light having a wavelength of from about 625 to about 635 nm.
Claim 20
Dependent Claim
16 words
The process of claim 12, wherein said photoreactive agent comprises HPD, DHE, or a mixture thereof.
Claim 21
Dependent Claim
15 words
The process of claim 18, wherein said carrier vehicle is a hydrophilic gel or cream.
Claim 22
Dependent Claim
35 words
The process of claim 19, wherein said carrier vehicle comprises about 50% w/w SD alcohol, the remainder comprising one or more of propylene glycol, purified water, polyoxyethylene lauryl ether dioctyl sodium sulfosuccinate, and the like.
Claim 23
Dependent Claim
11 words
The process of claim 20 wherein said carrier vehicle is DMSO.
Claim 24
Dependent Claim
29 words
The process of claim 20, wherein said carrier vehicle comprises 54% by weight SD alcohol, the remainder comprising propylene glycol, purified water, polyoxyethylene lauryl ether, and dioctyl sodium sulfosuccinate.
Claim 25
Dependent Claim
5 words
The product of claim 13.
Claim 26
Dependent Claim
72 words
A process for preparing a topical non-lyophilized composition for the photodynamic treatment of tissue growth caused by papillomavirus disease, comprising slowly evaporating an aqueous solution comprising from about 1 to about 7.5 mg/ml of a hematoporphyrin until it is concentrated to from about 20 to about 25 percent of its original volume; and rediluting the resulting concentration with gentle mixing with a carrier vehicle capable of deeply penetrating mammalian skin or mucosa.
Claim 27
Dependent Claim
72 words
A process for preparing a topical non-lyophilized composition for the photodynamic treatment of tissue growth caused by papillomavirus disease, comprising slowly evaporating an aqueous solution comprising from about 1 to about 7.5 mg/ml of a hematoporphyrin until it is concentrated to from about 20 to about 25 percent of its original volume; and rediluting the resulting concentration with gentle mixing with a carrier vehicle capable of deeply penetrating mammalian skin or mucosa.
Claim 28
Dependent Claim
16 words
The process of claim 24, further comprising vortexing said aqueous solution under vacuum with constant cooling.
Claim 29
Dependent Claim
17 words
The process of claim 25, further comprising placing said resulting concentration in an ice bath before rediluting.
Claim 30
Dependent Claim
20 words
The process of claim 24, further comprising rediluting the resulting concentrate until it is brought back to its original volume.
Claim 31
Dependent Claim
36 words
The process of claim 24, wherein said carrier vehicle comprises DMSO; a composition comprising 54% by weight SD alcohol, the remainder comprising propylene glycol, purified water, polyoxyethylene lauryl ether, and dioctyl sodium sulfosuccinate; or mixtures thereof.
Claim 32
Dependent Claim
5 words
The product of claim 24.
Claim 33
Dependent Claim
5 words
The product of claim 25.
Claim 34
Dependent Claim
5 words
The product of claim 27.
Claim 35
Independent Claim
34 words
A method of topically treating papillomavirus disease comprising applying the product of claims 29, 30 or 31 to an affected area of mammalian skin or mucosa, and irradiating the affected area with red light.
Claim 36
Independent Claim
87 words
A method of topically treating papillomavirus disease comprising slowly evaporating an aqueous solution comprising from about 1 to about 7.5 mg/ml of a hematoporphyrin until it is concentrated to about 20 to about 25 percent of its original volume; rediluting the resulting concentrate in a carrier vehicle capable of deeply penetrating mammalian skin or mucosa to form a topical composition; applying the topical composition to an affected area of mammalian skin or mucosa; and irradiating the affected area using light having a wavelength in the red spectrum.
Claim 37
Independent Claim
87 words
A method of topically treating papillomavirus disease comprising slowly evaporating an aqueous solution comprising from about 1 to about 7.5 mg/ml of a hematoporphyrin until it is concentrated to about 20 to about 25 percent of its original volume; rediluting the resulting concentrate in a carrier vehicle capable of deeply penetrating mammalian skin or mucosa to form a topical composition; applying the topical composition to an affected area of mammalian skin or mucosa; and irradiating the affected area using light having a wavelength in the red spectrum.
Claim 38
Dependent Claim
36 words
The method of claim 33, further comprising placing the aqueous solution in a vacuum of from about 20 to 25 mm Hg at a temperature from about 5° to about 15° C. during the concentration step.
Claim 39
Dependent Claim
15 words
The method of claim 34, further comprising vortexing the aqueous solution during the concentration step.
Claim 40
Dependent Claim
17 words
The method of claim 35, further comprising placing the resulting concentrate in an ice bath before rediluting.
Claim 41
Dependent Claim
15 words
The method of claim 36, wherein the resulting concentrate is rediluted to its original volume.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-05-14 | 1993-11-13 | 1994-05-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-05-14 | 1997-11-13 | 1998-05-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-05-14 | 2001-11-13 | 2002-05-15 | $7700.00 | Window Closed / Lapsed |